A Maximal Use Trial Evaluating the Pharmacokinetic Profile of MC2-01 Cream
Status:
Completed
Trial end date:
2018-08-04
Target enrollment:
Participant gender:
Summary
This is a phase 2, randomised, open-label, parallel-group, multicentre trial in which MC2-01
cream and calcipotriene [CAL]/betamethasone [BDP] ointment (comparator) is investigated in
subjects with clinically diagnosed extensive psoriasis vulgaris.
Phase:
Phase 2
Details
Lead Sponsor:
Drug Delivery Solutions Ltd. (part of MC2 Therapeutics) MC2 Therapeutics